The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells
Open accessAbstract
The immunosuppressive drug cyclosporin A (CsA) has considerable nephrotoxic side effects which seem to be related to its interference with the synthesis of vasoactive prostanoids. Therefore, the molecular mechanism of the effect of CsA on the synthesis of prostaglandin E2 (PGE2) was investigated in rat renal mesangial cells (RMC). CsA effectively inhibited the PGE2 synthesis induced by inflammatory cytokines such as interleukin 1 (IL-1) or tumor necrosis alpha (TNF alpha). The induction by IL-1 and the inhibition by CsA were reflected in the enzyme activity of the cyclooxygenase. The changes in activity could be correlated with the expression of the inducible cyclooxygenase isoform (COX2), which is characterized by its 4.4 kb mRNA: the expression of this enzyme was enhanced by IL-1 and suppressed by CsA on the mRNA and protein level as determined by Northern and Western blot analyses. Suppression of COX2 mRNA was also observed when the message was induced by LPS or ionophore A23187. The expression of the basal cyclooxygenase isoform (COX1), which was constitutively expressed in proliferating mesangial cells, was not affected by IL-1 or CsA. Interferon gamma, which did not induce prostaglandin synthesis or influence COX mRNA expression, augmented the expression of MHC antigens in RMC. This induction was insensitive to CsA treatment. We could thus show that the inducible cyclooxygenase isoform in mesangial cells is a molecular target for CsA providing a possible mechanism for t…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies involving angiotensin-I-converting enzyme inhibitors have demonstrated beneficial effects on proteinuria but have not demonstrated the superiority of blockade of the renin-angiotensin system in slowing the progression to end-stage renal disease over nonblockade forms of therapy. 14-20”
From Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (2001) · cites this paper as [15]
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1006/abio.1987.9999 · Cited by 65,515
The mechanism of action of cyclosporin A and FK506
Schreiber, S. L., & Crabtree, G. R. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90111-j · Cited by 2,127
cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase.
O’Banion, M. K., Winn, V. D., & Young, D. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.11.4888 · Cited by 812
Prostanoid biosynthesis and mechanisms of action
Smith, W. L. (1992) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1992.263.2.f181 · Cited by 551
The long-term course of cyclosporine-associated chronic nephropathy
Myers, B. D., Sibley, R. K., Newton, L., Tomlanovich, S. J., Boshkos, C., Stinson, E. B., Luetscher, J. A., Whitney, D. J., Krasny, D., Coplon, N. S., et al. (1988) · Kidney International · doi:10.1038/ki.1988.38 · Cited by 504
Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells.
Maier, J. A. M., Hla, T., & Maciag, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38515-1 · Cited by 479
The glomerular mesangial cell: an expanding role for a specialized pericyte
Schlöndorff, D. (1987) · The FASEB Journal · doi:10.1096/fasebj.1.4.3308611 · Cited by 438
Myers, P. D. B. D. (1986) · Kidney International · doi:10.1038/ki.1986.280 · Cited by 331
English, J., Evan, A. P., Houghton, D. C., & Bennett, W. M. (1987) · Transplantation · doi:10.1097/00007890-198707000-00027 · Cited by 298
Cited by
Sorted by citations
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,527
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 1,406
Preserving renal function in adults with hypertension and diabetes: A consensus approach
Bakris, G. L., Williams, M. E., Dworkin, L. D., Elliott, W. J., Epstein, M., Toto, R. D., Tuttle, K. R., Douglas, J. G., Hsueh, W. A., & Sowers, J. R. (2000) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2000.16225 · Cited by 1,396
Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II
Dinchuk, J. E., Car, B. D., Focht, R. J., Johnston, J. J., JAFFEE, B. D., Covington, M. B., Contel, N. R., Eng, V. M., Collins, R. J., Czerniak, P. M., et al. (1995) · Nature · doi:10.1038/378406a0 · Cited by 967
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy
Barnett, A. H., Bain, S. C., Bouter, P., Karlberg, B., Madsbad, S., Jervell, J., & Mustonen, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042274 · Cited by 910
Feng, L., Xia, Y., García, G., Hwang, D. H., & Wilson, C. B. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117842 · Cited by 480
Diabetes Mellitus and Associated Hypertension, Vascular Disease, and Nephropathy
Sowers, J. R., & Epstein, M. (1995) · Hypertension · doi:10.1161/01.hyp.26.6.869 · Cited by 436
Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy
Wm, B., DEMATTOS, A. M., Meyer, M. M., Andoh, T. F., & Barry, J. M. (1996) · Kidney International · doi:10.1038/ki.1996.415 · Cited by 435
Bakris, G. L., Copley, J. B., Vicknair, N., Sadler, R., & Leurgans, S. (1996) · Kidney International · doi:10.1038/ki.1996.480 · Cited by 417
IL‐1β induces COX2, MMP‐1, ‐3 and ‐13, ADAMTS‐4, IL‐1β and IL‐6 in human tendon cells
Tsuzaki, M., Guyton, G. P., Garrett, W. E. J., Archambault, J. M., Herzog, W., Almekinders, L. C., Bynum, D. K., Yang, X., & Banes, A. J. (2003) · Journal of Orthopaedic Research® · doi:10.1016/s0736-0266(02)00141-9 · Cited by 366
Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists
Taal, M. W., & Brenner, B. M. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00031.x · Cited by 439
Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease
Garg, J. P., & Bakris, G. L. (2002) · Vascular Medicine · doi:10.1191/1358863x02vm412ra · Cited by 276
Long-term Effects of Antihypertensive Agents on Proteinuria and Renal Function
Maki, D. D. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430100105012 · Cited by 269
Vijan, S. S., & Hayward, R. A. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-7-200304010-00018 · Cited by 262
Diabetic nephropathy: Prevention and treatment
Parving, H. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00020.x · Cited by 225
Pre-treatment with IL-1β enhances the efficacy of MSC transplantation in DSS-induced colitis
Fan, H., Zhao, G., Liu, L., Liu, F., Gong, W., Liu, X., Yang, L., Wang, J., & Hou, Y. (2012) · Cellular and Molecular Immunology · doi:10.1038/cmi.2012.40 · Cited by 224
Rossing, K., Jacobsen, P. K., Pietraszek, L., & Parving, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2268 · Cited by 224
Iñiguez, M. A., Martı́nez-Martı́nez, S., Punzón, C., Redondo, J. M., & Fresno, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001381200 · Cited by 205
Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy
Rossing, K., Christensen, P. K., Jensen, B. R., & Parving, H. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.95 · Cited by 202
Prevention and Treatment of Diabetic Renal Disease in Type 2 Diabetes
Remuzzi, G., Macia, M. L., & Ruggenenti, P. L. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005121324 · Cited by 192
Iñiguez, M. A., Punzón, C., & Fresno, M. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.111 · Cited by 185
Selective inhibition of cyclooxygenase 2
Klein, T., Nüsing, R. M., Pfeilschifter, J. M., & Ullrich, V. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90205-4 · Cited by 180
Regulation of prostaglandin endoperoxide synthase (cyclooxygenase) isozyme expression
Goppelt‐Struebe, M. (1995) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/0952-3278(95)90039-x · Cited by 134
Self-citationAntihypertensive treatment in patients with type-2 diabetes mellitus
Zanchetti, A., & Ruilope, L. M. (2002) · Journal of Hypertension · doi:10.1097/00004872-200211000-00001 · Cited by 133
Management of Patients with Chronic Renal Insufficiency in the Northeastern United States
Kausz, A. T., Khan, S. S., Abichandani, R., Kazmi, W., Obrador, G. T., Ruthazer, R., & Pereira, B. J. G. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1271501 · Cited by 126
Burnier, M., & Zanchi, A. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000191244.91314.9d · Cited by 120
Attur, M. G., Patel, R., Thakker, G. D., Vyas, P., Levartovsky, D., Patel, P., Naqvi, S., Raza, R., Patel, K., Abramson, D., et al. (2000) · Inflammation Research · doi:10.1007/pl00000199 · Cited by 122
Maione, A., Navaneethan, S. D., Graziano, G., Mitchell, R. L., Johnson, D. W., Mann, J. F. E., Gao, P., Craig, J. C., Tognoni, G., Perkovic, V., et al. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq792 · Cited by 114
Cyclooxygenase‐2 Is Upregulated in Inflamed Gingival Tissues
Morton, R. S., & Dongari‐Bagtzoglou, A. I. (2001) · Journal of Periodontology · doi:10.1902/jop.2001.72.4.461 · Cited by 110
Cordonnier, D., Pinel, N., Barro, C. D., Maynard, C., Zaoui, P., Halimi, S., de Ligny, B. H., Reznic, Y., Simon, D., & Bilous, R. W. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1061253 · Cited by 109
Böhlen, L., de Courten, M., & Weidmann, P. U. (1994) · American Journal of Hypertension · doi:10.1093/ajh/7.9.84s · Cited by 107
Diabetic Nephropathy: The Proteinuria Hypothesis
Williams, M. E. (2005) · American Journal of Nephrology · doi:10.1159/000084286 · Cited by 108
Critical care issues in patients after liver transplantation
Razonable, R. R., Findlay, J. Y., O’Riordan, A., Burroughs, G. S., Ghobrial, R. M., Agarwal, B., Davenport, A., & Gropper, M. A. (2011) · Liver Transplantation · doi:10.1002/lt.22291 · Cited by 104
Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus
Ruggenenti, P. L., Lauria, G., Iliev, I. P., Fassi, A., Parvanova, A. I., Rota, S., Chiurchiu, C. R., Barlovič, D. P., Sghirlanzoni, A., Lombardi, R., et al. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.174474 · Cited by 103
Multiple Controls in Inflammation
Cirino, G. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00215-3 · Cited by 95
new insights into prostaglandins and mucosal defence
Wallace, J. L., & Tigley, A. W. (1995) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1995.tb00377.x · Cited by 92
The development of gastrointestinal-sparing nonsteroidal anti-inflammatory drugs
Wallace, J. L., & Cirino, G. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90083-3 · Cited by 88
KESTER, M. A., Coroneos, E., Thomas, P. J., & Dunn, M. J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31684-8 · Cited by 86
Transient expression of prostaglandin endoperoxide synthase-2 during mouse macrophage activation
Riese, J., Hoff, T., Nordhoff, A., DeWitt, D. L., Resch, K., & Kaever, V. (1994) · Journal of Leukocyte Biology · doi:10.1002/jlb.55.4.476 · Cited by 85
Self-citationEvolving strategies for renoprotection: diabetic nephropathy
Parving, H., Hovind, P. H., Rossing, K., & Andersen, S. (2001) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200107000-00006 · Cited by 82
Hansen, H. P., Rossing, P. R., Tarnow, L., Nielsen, F. S., Jensen, B. R., & Parving, H. (1995) · Kidney International · doi:10.1038/ki.1995.238 · Cited by 82
Phisitkul, K., Hegazy, K., Chuahirun, T., Hudson, C., Wesson, D. E., Simoni, J. M., & Rajab, H. (2008) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e318156b799 · Cited by 75
Stroebel, M., & Goppelt‐Struebe, M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31602-2 · Cited by 75
Self-citationGonzález-Navajas, J. M., Law, J. K., Nguyen, K. P., Bhargava, M., Corr, M., Varki, N. M., Eckmann, L., Hoffman, H. M., Lee, J., & Raz, E. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20101326 · Cited by 74
Ge, Y., Xie, H., Li, S., Jin, B., Hou, J., Zhang, H., Shi, M., & Liu, Z. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-134 · Cited by 71
Sugimoto, T., Haneda, M., Sawano, H., Isshiki, K., Maeda, S., Koya, D., Inoki, K., Yasuda, H., Kashiwagi, A., & Kikkawa, R. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1271359 · Cited by 72
Optimal Dose of Candesartan for Renoprotection in Type 2 Diabetic Patients With Nephropathy
Rossing, K., Christensen, P. K., Hansen, B. V., Carstensen, B., & Parving, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.1.150 · Cited by 72
Tanaka, K., Kawasaki, H., Kurata, K., Aikawa, Y., Tsukamoto, Y., & Inaba, T. (1995) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.67.305 · Cited by 71
Evidence‐based guide to slowing the progression of early renal insufficiency
Johnson, D. W. (2004) · Internal Medicine Journal · doi:10.1111/j.1444-0903.2004.t01-6-.x · Cited by 70
The Effects of a High-Fat Diet on Inflammatory Bowel Disease
Dang, Y., Ma, C., Chen, K., Chen, Y., Jiang, M., Hu, K., Li, L., Zeng, Z., & Zhang, H. (2023) · Biomolecules · doi:10.3390/biom13060905 · Cited by 69
PRICE, D., DEOLIVEIRA, J., Fisher, N. D. L., WILLIAMS, G., & Hollenberg, N. K. (1999) · American Journal of Hypertension · doi:10.1016/s0895-7061(00)86960-5 · Cited by 64
New Anti-inflammatory Treatment Strategy in Alzheimer’s Disease
Sugaya, K., Uz, T., Kumar, V., & Manev, H. (2000) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.82.85 · Cited by 65
Eberhardt, W., Akool, E., Rebhan, J. ̈., Frank, S., Beck, K., Franzen, R., Hamada, F. M. A., & Pfeilschifter, J. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202008200 · Cited by 63
Pharmacology of immunosuppressive medications used in renal diseases and transplantation
de Mattos, A. M., Olyaei, A. J., & Bennett, W. M. (1996) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(96)90246-2 · Cited by 63
Endres, S., Whitaker, R., GHORBANI, R., Meydani, S. N., & Dinarello, C. A. (1996) · Immunology · doi:10.1046/j.1365-2567.1996.472535.x · Cited by 61
Schneider, A., Harendza, S., Zahner, G., Jocks, T., Wenzel, U. O., Wolf, G., Thaiss, F., Helmchen, U. M., & Stahl, R. A. K. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00265.x · Cited by 61
Sawano, H., Haneda, M., Sugimoto, T., Inoki, K., Koya, D., & Kikkawa, R. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00351.x · Cited by 58
Endothelin-1 induction of cyclooxygenase-2 expression in rat mesangial cells
Hughes, A. K., Padilla, E., Kutchera, W. A., Michael, J. R., & Kohan, D. E. (1995) · Kidney International · doi:10.1038/ki.1995.6 · Cited by 54
Ghosh, S. S., Krieg, R., Massey, H. D., Sica, D. A., Fakhry, I., Ghosh, S., & Gehr, T. W. B. (2011) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00356.2010 · Cited by 53
Clostridium difficile infection in HIV-seropositive individuals and transplant recipients
Collini, P., Bauer, M. P., Kuijper, E. J., & Dockrell, D. H. (2011) · Journal of Infection · doi:10.1016/j.jinf.2011.12.003 · Cited by 53
Cyclooxygenase-2 (COX-2) and the kidney: current status and potential perspectives
Schneider, A., & Stahl, R. A. K. (1998) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/13.1.10 · Cited by 53
Renal and Cardiovascular Protection in Type 2 Diabetes Mellitus
Deferrari, G., Ravera, M., Deferrari, L., Vettoretti, S., Ratto, E., & Parodi, D. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000032544.37147.ae · Cited by 53
Wesche, H., Neumann, D., Resch, K., & Martin, M. U. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00713-2 · Cited by 53
Self-citationRenal Protection and Antihypertensive Drugs
Salvetti, A., Mattei, P., & Sudano, I. (1999) · Drugs · doi:10.2165/00003495-199957050-00002 · Cited by 51
The Role of Glycosaminoglycans and Sulodexide in the Treatment of Diabetic Nephropathy
Abaterusso, C., & Gambaro, G. (2006) · Treatments in Endocrinology · doi:10.2165/00024677-200605040-00002 · Cited by 49
Prevention and Treatment of Diabetic Nephropathy
Ravera, M., Ratto, E., Vettoretti, S., Parodi, D., & Deferrari, G. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004110957 · Cited by 49
Jenkins, J. K., Huang, H. M., Ndebele, K., & Salahudeen, A. K. (2001) · Transplantation · doi:10.1097/00007890-200101270-00028 · Cited by 48
Effect of cyclosporin‐A on the blood–retinal barrier permeability in streptozotocin‐induced diabetes
do Carmo, A., Cunha-Vaz, J. G., Carvalho, A. P., & Lopes, M. C. (2000) · Mediators of Inflammation · doi:10.1080/09629350020025764 · Cited by 48
Hartner, A., Pahl, A. M., Brune, K., & Goppelt‐Struebe, M. (2000) · Inflammation Research · doi:10.1007/pl00000215 · Cited by 48
Self-citationImpaired autoregulation of the glomerular filtration rate in patients with nondiabetic nephropathies
Christensen, P. K., Hommel, E. E., Clausen, P., Feldt‐Rasmussen, B., & Parving, H. H. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00676.x · Cited by 47
Blood Pressure Lowering for the Prevention and Treatment of Diabetic Kidney Disease
Thomas, M. C., & Atkins, R. C. (2006) · Drugs · doi:10.2165/00003495-200666170-00005 · Cited by 45
Jerums, G., Panagiotopoulos, S., Premaratne, E., Power, D. A., & MacIsaac, R. J. (2008) · American Journal of Nephrology · doi:10.1159/000117461 · Cited by 44
Péchère-Bertschi, A., Greminger, P., Hess, L., Philippé, J., & Ferrari, P. (2005) · Blood Pressure · doi:10.1080/08037050500340018 · Cited by 42
Song, Y., Lim, J.-Y., Lim, T., Im, K.-I., Kim, N., Nam, Y.-S., Jeon, Y., Shin, J. C., Ko, H. S., Park, I. Y., et al. (2020) · World Journal of Stem Cells · doi:10.4252/wjsc.v12.i9.1032 · Cited by 44
Marie, V., & Silva, J. E. (1998) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199806)175:3 · Cited by 13
Self-citationMANAGEMENT OF EARLY NEPHROPATHY IN DIABETIC PATIENTS
Mogensen, C. E. (1995) · Annual Review of Medicine · doi:10.1146/annurev.med.46.1.79 · Cited by 34
Goppelt‐Struebe, M., Hahn, A. F., Stroebel, M., & Reiser, C. O. A. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3390329 · Cited by 34
Self-citationRibeiro, A. B. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x75041 · Cited by 33
The Clinical Implications of Inhibition of the Inducible Form of Cyclo-Oxygenase
Richardson, C., & Emery, P. (1996) · Drug Safety · doi:10.2165/00002018-199615040-00003 · Cited by 32
NSAID Gastroenteropathy: Past, Present and Future
Wallace, J. L. (1996) · Canadian Journal of Gastroenterology · doi:10.1155/1996/850710 · Cited by 32
Robida, A. M., Xu, K., Ellington, M. L., & Murphy, T. J. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23101-1 · Cited by 31
Slowing the Progression of Adult Chronic Kidney Disease
Taal, M. W. (2004) · Drugs · doi:10.2165/00003495-200464200-00002 · Cited by 31
The effect of silibinin on experimental cyclosporine nephrotoxicity
Zima, T., KAMENÍKOVÁ, L., Kalousová, M., Buchar, E., Crkovska, J., & Tesař, V. (1998) · Renal Failure · doi:10.3109/08860229809045136 · Cited by 28
Angiotensin‐Converting Enzyme Inhibitors and Type 2 Diabetic Nephropathy: A Meta‐Analysis
Hamilton, R. A., Kane, M. P., & Demers, J. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.7.909.32726 · Cited by 28
Dey, I., Beck, P. L., & Chadee, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061891 · Cited by 26
Gene expression changes in human small airway epithelial cells exposed to Δ9-tetrahydrocannabinol
Sarafian, T. A., Habib, N. A., Mao, J. T., Tsu, I.-H., Yamamoto, M. L., Hsu, E. L., Tashkin, D. P., & Roth, M. D. (2005) · Toxicology Letters · doi:10.1016/j.toxlet.2005.03.008 · Cited by 27
Optimizing Therapy in the Diabetic Patient with Renal Disease
Deferrari, G., Ravera, M., Berruti, V., Leoncini, G., & Deferrari, L. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000105881.71167.44 · Cited by 26
Sica, D. A. (2003) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2003.02836.x · Cited by 26
Latin American consensus on diabetes mellitus and hypertension
Burlando, G., nchez, R. A. S., Ramos, F. H., Mogensen, C. E., & Zanchetti, A. (2004) · Journal of Hypertension · doi:10.1097/00004872-200412000-00001 · Cited by 25
Goppelt‐Struebe, M., Stroebel, M., & Hoppe, J. (1996) · Kidney International · doi:10.1038/ki.1996.288 · Cited by 25
Self-citationCrook, E. D., Harris, J., Oliver, B. L., Fleischmann, E. H., Crenshaw, G. D., & Taylor, R. T. (2001) · Journal of Investigative Medicine · doi:10.2310/6650.2001.33974 · Cited by 25
Losartan in diabetic nephropathy
Perico, N., Ruggenenti, P. L., & Remuzzi, G. (2004) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2.4.473 · Cited by 23
Macchioni, P. L., Boiardi, L., Cremonesi, T., Battistel, B., Casadei-Maldini, M., Beltrandi, E., Mancini, R., & Salvarani, C. (1998) · Rheumatology International · doi:10.1007/s002960050050 · Cited by 23
Glutathione mediates LPS‐stimulated COX‐2 expression via early transient p42/44 MAPK activation
Chen, J., Berry, L. C., Christman, B. W., & Meyrick, B. O. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10353 · Cited by 22
Sakai, M., Uchii, M., Myojo, K., Kitayama, T., & Kunori, S. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.04.023 · Cited by 21
López‐Parra, M., Clària, J., Titos, E., Planagumà, A., Párrizas, M., Masferrer, J. L., Jiménez, W., Arroyo, V., Rivera, F., & Rodés, J. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.09.011 · Cited by 21
Alsalemi, N., Sadowski, C. A., Elftouh, N., Louis, M., Kilpatrick, K., Houle, S. K. D., & Lafrance, J. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02763-1 · Cited by 21
Garg, J. P., & Bakris, G. L. (2002) · Current Hypertension Reports · doi:10.1007/s11906-002-0005-6 · Cited by 17
Metadata
- Authors
- Martin, M., Neumann, D., Hoff, T., Resch, K., DeWitt, D. L., & Goppelt-Struebe, M.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Corresponding author
- Martin, Michael
- ORCID
- Neumann, Detlef
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 1994-01
- Volume
- 45
- Issue
- 1
- Pages
- 150-158
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W1965476867
- Cited by
- 178
- References
- 42
- Citations by year
- 2025: 1 · 2023: 1 · 2022: 4 · 2020: 1 · 2015: 3 · 2014: 3 · 2013: 3 · 2012: 1
- FWCI
- 10.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Kidney International (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- cyclosporine, cyclooxygenase-2, interleukin-1, renal mesangial cells, prostaglandin E2 synthesis, cyclooxygenase-1, TNF-α, interferon-gamma, MHC antigen expression, cyclosporine nephrotoxicity, inflammatory cytokines
- MeSH terms
- Animals, Histocompatibility Antigens Class II, Cells, Cultured, Glomerular Mesangium, Interleukin-1, Male, Prostaglandin-Endoperoxide Synthases, Recombinant Proteins, RNA, Messenger, Dinoprostone, Histocompatibility Antigens Class I, Cytokines, Cyclosporine, Cyclooxygenase Inhibitors, Rats, Sprague-Dawley, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review